Investment and Company Research
MICROCAP HOT TOPICS
September 17, 2013
Breast Cancer Patients Could Benefit
From Plandaí Phytofare™ Citrus Products
With October (The Breast Cancer Awareness Month) around the corner, it is interesting to note that Plandaí Biotechnology, Inc.’s (OTCQB – PLPL - $0.55 – Spec Buy) Phytofare™ Citrus Products may prove to be useful in the fight against breast cancer due to the high bioavailability of its citrus bioflavonoid product.
For example, many breast cancer patients who undergo surgery to treat breast cancer suffer from a common side effect known as Lymphedema. This condition is marked by intense swelling of the arm due to damage done to the lymph nodes in the surgical procedure. An older study from about 15 years ago demonstrated significantly less swelling in patients who took a bioflavonoid supplement in a double blind study of 57 women. (Pecking AP, Fevrier B, Wargon C, et al. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology1997; 48:93-98)
Bioflavonoids are naturally occurring compounds extracted from plants and rich in antioxidants and are found in fruits like lemons that contain vitamins A & C and a variety of minerals including potassium and pectin. These bioflavonoids help protect the nutrients from oxidation in the body. To that end, Plandaí is set to release the Phytofare™ Catechin Complex in the coming months and the citrus-based Limonoid Glycoside Complex products in 2014. The Phytofare™ citrus bioflavonoid product will be 7 to 12 times more effective from a blood absorption perspective than any other bioflavonoid supplement on the market today. Using dietary supplements similar to this has been shown effective in treating all sorts or ailments and sicknesses like Lymphedema in the past.
Fast forward to today where many organizations like BreastCancer.org are recommending dietary supplements and general diets that include citrus bioflavonoids to aid in fighting the effects of Lymphedema. Unfortunately, Lymphedema will continue to be a common problem as breast cancer remains a huge issue in women’s health and bioflavonoids in generally have very poor bioavailability—often around 5% absorption. That can dramatically change due to the high bioavailability associated with its citrus bioflavonoid product.
Breast cancer remains at the forefront of women’s health concerns. According to American Cancer Society an estimated 1 in 8 women will be diagnosed with breast cancer in their lifetime and over 235,000 women expected to be diagnosed per year in and approximately 40,000 will die from the disease.
Breast cancer surgery remains a very popular treatment in fighting the disease. Lymphedema occurs as a side effect of this surgery in some cases but also occurs in a larger cross section of society in general. The Plandaí Phytofare™ Citrus product will aid symptoms of this ailment and provide better results than competitors because of its superior bioavailability, or absorption in the blood, as mentioned above. This market is yet another that should help Plandaí generate revenue as the Company ramps up production by year-end 2013 and into 2014.
For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since May 2013, Goldman Small Cap Research has been compensated $500 per article by a third party and $4,000 for a research report service.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information and our own due diligence. The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com